αB-crystallin induces by matrix detachment via ERK is critical in inhibition of anoikis

 

Anoikis, extracellular matrix detachment-induced apoptosis, plays a critical role in maintaining tissue structure by eliminating epithelial cells that have been displaced from their extracellular matrix. The resistance of anoikis is a defining characteristic of metastatic carcinoma cells. Malin et al. identified an matrix detachment-induced antiapoptotic molecular chaperone, αB-crystallin, confers anoikis resistance. The article was published in Oncogene.

 

Researchers found matrix detachment suppress activity of extracellular signal-regulated kinase (ERK) and increases αB-crystallin protein and messenger RNA (mRNA) levels. In addition, they found ERK signaling negatively correlated with αB-crystallin protein and mRNA levels, indicating ERK inhibition is both necessary and sufficient for αB-crystallin induction. Furthermore, by silencing αB-crystallin in two different matastatic carcinoma cell lines, they observed an increase of matrix detachment-induced caspase activation and apoptosis, as well as a reduction of viable circulating tumor cells, but did not affect viability of adherent cancer cells and primary tumor growth. The findings suggested that αB-crystallin works as a novel regulator of anoikis resistance and a promising therapeutic target against tumor metastasis.

 

Reference:
Oncogene. 2015 Feb 16. doi: 10.1038/onc.2015.12. 

Related Products

Cat.No.	Product Name	Information
S1105	LY294002	LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
S7008	PP2	PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
S1020	PD184352 (CI-1040)	PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis.
S1008	Selumetinib (AZD6244)	Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Related Targets

Src MEK PI3K Autophagy